ERCC4 and neoplasm: Furthermore, we used the tumor-bearing mice to confirm that the XPF–ERCC1 blocker enhanced the therapeutic effect of 5-FU or OXA; it also improved the 5-FU-based CRT or OXA-based CRT therapy for RC.